AstraZeneca said its Imfinzi treatment did not produce a significant improvement for cervical cancer patients over treatment by chemoradiotherapy (CRT) on its own.
In a phase 3 Calla trial, Imfinzi was given to patients together with CRT but there was no statistically significant benefit compared with CRT without Imfinzi, the company said.
Susan Galbraith, AstraZeneca’s executive vice president for oncology research and development, said: “Calla tested a novel immunotherapy approach in locally advanced cervical cancer, a devastating and complex disease where many patients progress following available treatments.
“While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development programme, exploring the benefits of Imfinzi in many tumour types.”
AstraZeneca shares rose 0.6% to £97.90 at 08:44 GMT.
